Inhibikase ups incentive pool by 3M shares
Inhibikase Therapeutics, Inc. held its 2026 annual meeting of stockholders in a virtual format, where all six management proposals were approved.
Rhea-AI Filing Summary
Inhibikase Therapeutics, Inc. held its 2026 annual meeting of stockholders in a virtual format, where all six management proposals were approved. Stockholders backed an amendment to the 2020 Equity Incentive Plan, increasing the shares reserved for issuance by 3,000,000 common shares.
They also approved a Certificate of Amendment to limit the liability of certain officers as permitted by Delaware law, ratified CohnReznick LLP as independent auditor for 2026, and supported executive compensation on an advisory basis. Directors Arvind Kush and Dennis Berman were re‑elected as Class III directors, and investors chose to hold future say‑on‑pay votes annually.
Positive
- None.
Negative
- None.
8-K Event Classification
4 items: 5.02, 5.03, 5.07, 9.01
4 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Equity plan share increase: 3,000,000 shares
Votes for Arvind Kush: 70,338,595 votes
Votes for Dennis Berman: 64,127,395 votes
+4 more
7 metrics
Equity plan share increase
3,000,000 shares
Additional common shares reserved under 2020 Equity Incentive Plan
Votes for Arvind Kush
70,338,595 votes
Election as Class III director at 2026 annual meeting
Votes for Dennis Berman
64,127,395 votes
Election as Class III director at 2026 annual meeting
Auditor ratification support
106,910,712 votes for
Ratification of CohnReznick LLP for fiscal year 2026
Officer liability amendment support
82,321,246 votes for
Approval of certificate amendment limiting certain officer liability
Say-on-pay support
61,237,304 votes for
Advisory approval of named executive officer compensation
Annual say-on-pay frequency votes
77,456,671 votes
Support for 1-year frequency of advisory compensation votes
Key Terms
2020 Equity Incentive Plan, Certificate of Amendment, broker non-votes, non-binding, advisory basis, +1 more
5 terms
2020 Equity Incentive Plan financial
"an amendment to the Company’s 2020 Equity Incentive Plan to increase the authorized number of shares"
Certificate of Amendment regulatory
"approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”)"
A certificate of amendment is an official filing that updates a company’s founding documents—its legal “rulebook” that sets share structure, voting rules, name and basic purpose. Think of it like changing the blueprint of a building: small changes are paperwork, big ones can alter who owns how much and who controls decisions. Investors watch these filings because they can affect share counts, voting power, dilution and company value.
broker non-votes financial
"Broker Non-Votes | | | 23,911,956"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
non-binding, advisory basis financial
"To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers."
A non-binding, advisory basis means a recommendation or decision that carries no legal force and does not obligate the parties to act; it’s similar to a friendly suggestion rather than a signed promise. For investors, this matters because such guidance can influence market expectations and management plans but offers no guarantee of follow-through, so investors should treat it as informative input rather than a firm commitment.
independent registered public accounting firm financial
"To ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Inhibikase Therapeutics (IKT) stockholders approve regarding the equity incentive plan?
Stockholders approved an amendment to the 2020 Equity Incentive Plan, increasing shares of common stock reserved for issuance by 3,000,000 shares. This expands the pool available for future equity awards to employees, directors, and other eligible participants under the plan.
What governance changes did Inhibikase Therapeutics (IKT) adopt for officer liability?
Stockholders approved a Certificate of Amendment to the Amended and Restated Certificate of Incorporation to limit the liability of certain officers as permitted by Delaware law. The amendment was filed and became effective on June 26, 2026, upon submission to the Delaware Secretary of State.
Who was elected to Inhibikase Therapeutics (IKT) board at the 2026 annual meeting?
Stockholders elected Arvind Kush and Dennis Berman as Class III directors. Kush received 70,338,595 votes for and Berman received 64,127,395 votes for, each serving until the 2029 annual meeting or until earlier death, resignation, or removal.
Which auditor did Inhibikase Therapeutics (IKT) stockholders ratify for 2026?
Stockholders ratified CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification received 106,910,712 votes for, 96,428 against, and 13,532 abstentions, with no broker non‑votes recorded.
How did Inhibikase Therapeutics (IKT) investors vote on executive compensation?
On a non-binding advisory basis, stockholders approved compensation of named executive officers with 61,237,304 votes for, 21,648,671 against, and 222,741 abstentions. This advisory vote expresses support for the company’s current executive pay programs but does not directly change compensation.
What frequency did Inhibikase Therapeutics (IKT) investors choose for say-on-pay votes?
Stockholders favored an annual say-on-pay vote, with 77,456,671 votes for 1 year, 1,379 for 2 years, and 5,363,879 for 3 years. The company determined it will hold advisory votes on executive compensation each year until the next frequency vote.
AI-generated analysis. How Rhea-AI works. Not financial advice.
